Cadence gets US FDA complete response letter for intravenous paracetamol
This article was originally published in Scrip
Executive Summary
The US FDA has hit Cadence Pharmaceuticals with a complete response letter for its intravenous formulation of acetaminophen (paracetamol), which it intends to market under the name Ofirmev.